The EFHD1 Knockout A-549 Polyclonal Cells product from Ascent Research provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EFHD1 gene in the human A-549 lung epithelial carcinoma cell line. This pooled population of edited cells offers a genetically disrupted EFHD1 locus, enabling loss-of-function studies without the need for clonal isolation. The CRISPR/Cas9-mediated gene disruption serves as a versatile tool for investigating EFHD1-dependent processes in cancer cell biology.
The A-549 host cell line was originally derived from the lung adenocarcinoma tissue of a 58-year-old male and is widely employed as a model for non-small cell lung cancer (NSCLC). A-549 cells exhibit key features of lung adenocarcinoma, including epithelial morphology, anchorage-independent growth, and metastatic potential. Their well-characterized signaling networks make them a suitable platform for dissecting molecular mechanisms driving tumor progression and invasion.
EFHD1 encodes a calcium-binding adaptor protein that integrates calcium signaling with cytoskeletal dynamics. Upon elevation of intracellular calcium, EFHD1 undergoes conformational changes that promote its interaction with key components of the store-operated calcium entry (SOCE) machinery, including STIM1 and the Orai1 calcium channel. This interaction modulates calcium influx, which in turn influences downstream effectors such as Rac1 and RhoA, small GTPases that govern actin polymerization. EFHD1 also directly associates with actin filaments and fascin, a bundling protein, to stabilize protrusive structures at the leading edge of migrating cells. Additionally, EFHD1 participates in focal adhesion turnover by regulating FAK phosphorylation and cofilin activity, both of which are downstream of calcium and TNF-alpha signals. These interactions position EFHD1 at the nexus of actin cytoskeleton remodeling, cell adhesion, and migration.
In A-549 lung adenocarcinoma cells, disruption of EFHD1 impairs calcium-dependent migration and invasiveness, as evidenced by reduced wound closure and transwell invasion capacity. The knockout model recapitulates the metastatic suppression observed in EFHD1-silenced tumor cells, underscoring the protein??s role in promoting aggressive cancer phenotypes. This polyclonal cell population thus serves as a physiologically relevant system for exploring how calcium-responsive adaptors drive metastatic dissemination in NSCLC and other carcinomas.
Typical applications of these EFHD1 knockout A-549 cells include detailed investigation of cancer cell motility, calcium signaling, and actin dynamics. Functional assays such as wound healing and transwell invasion quantify metastatic capacity, while F-actin staining and calcium imaging reveal cytoskeletal and calcium changes. Biochemical analyses, including western blotting for EFHD1, co-immunoprecipitation of STIM1/Orai1 complexes, and FAK phosphorylation assessment, dissect molecular mechanisms. These cells also aid drug discovery for metastasis. For technical inquiries, please contact Ascent Research.
